Genmab A/S - GMAB Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $48.50
Forecasted Upside: 71.20%
Number of Analysts: 13
Breakdown:
3 Sell Ratings
2 Hold Ratings
8 Buy Ratings
0 Strong Buy Ratings

^$28.33 As of 04/18/2024 01:00 AM ET

▼ -0.2 (-0.70%)

1 month | 3 months | 12 months

Get New Genmab A/S Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for GMAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GMAB

^$48.50

▲ +71.20% Upside Potential

This price target is based on 13 analysts offering 12 month price targets for Genmab A/S in the last 3 months. The average price target is $48.50, with a high forecast of $50.00 and a low forecast of $46.00. The average price target represents a 71.20% upside from the last price of $28.33.

Current Consensus is Hold

The current consensus among 13 investment analysts is to hold stock in Genmab A/S. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
8 buy ratings
2 hold ratings
3 sell ratings

Ratings as of

10/26/2022

0 strong buy ratings
8 buy ratings
2 hold ratings
3 sell ratings

Ratings as of

1/24/2023

0 strong buy ratings
8 buy ratings
2 hold ratings
3 sell ratings

Ratings as of

4/24/2023

0 strong buy ratings
8 buy ratings
2 hold ratings
3 sell ratings

Ratings as of

7/23/2023

0 strong buy ratings
8 buy ratings
2 hold ratings
3 sell ratings

Ratings as of

10/21/2023

0 strong buy ratings
8 buy ratings
2 hold ratings
3 sell ratings

Ratings as of

1/19/2024

0 strong buy ratings
8 buy ratings
2 hold ratings
3 sell ratings

Ratings as of

3/19/2024

0 strong buy ratings
8 buy ratings
2 hold ratings
3 sell ratings

Ratings as of

4/18/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/4/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$50.00	Low
3/27/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$50.00	Low
3/26/2024	Morgan Stanley	Reiterated Rating	Underweight ➝ Underweight		Low
3/26/2024	Truist Financial	Reiterated Rating	Buy ➝ Buy	$50.00	Low
3/6/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$50.00	Low
2/23/2024	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$46.00 ➝ $48.00	Low
2/20/2024	Truist Financial	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $50.00	Low
2/20/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$50.00	Low
1/29/2024	HC Wainwright	Boost Target	Buy ➝ Buy	$49.00 ➝ $50.00	Low
1/22/2024	Citigroup	Downgrade	Neutral ➝ Sell		Low
12/6/2023	UBS Group	Upgrade	Neutral ➝ Buy		Low
11/28/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$49.00	Low
11/20/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$49.00	Low
11/10/2023	Deutsche Bank Aktiengesellschaft	Upgrade	Hold ➝ Buy		Low
11/8/2023	DNB Markets	Upgrade	Sell ➝ Buy		Low
11/7/2023	HC Wainwright	Lower Target	Buy ➝ Buy	$51.00 ➝ $49.00	Low
10/18/2023	BNP Paribas	Initiated Coverage	Underperform		Low
10/18/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$51.00	Low
10/13/2023	BTIG Research	Boost Target	Buy ➝ Buy	$44.00 ➝ $46.00	Low
10/12/2023	Nordea Equity Research	Downgrade	Buy ➝ Hold		Low
9/26/2023	Truist Financial	Reiterated Rating	Buy ➝ Buy	$54.00	Low
9/6/2023	Truist Financial	Reiterated Rating	Buy ➝ Buy	$54.00	Low
9/6/2023	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform		Low
9/5/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$51.00	Low
8/24/2023	BTIG Research	Initiated Coverage	Buy		Low
8/15/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy		Low
7/31/2023	Morgan Stanley	Reiterated Rating	Underweight ➝ Underweight		Low
7/31/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy		Low
7/24/2023	Morgan Stanley	Reiterated Rating	Underweight ➝ Underweight		Low
7/14/2023	HSBC	Initiated Coverage	Buy		Low
5/31/2023	UBS Group	Initiated Coverage	Neutral		Low
5/22/2023	HC Wainwright	Boost Target		$47.00 ➝ $51.00	Low
5/16/2023	HC Wainwright	Boost Target		$46.00 ➝ $47.00	Low
5/12/2023	Morgan Stanley	Initiated Coverage	Underweight		Low
4/20/2023	HC Wainwright	Reiterated Rating	Buy		Low
2/23/2023	Danske	Upgrade	Hold ➝ Buy		Low
2/6/2023	SVB Leerink	Boost Target	Market Perform	$33.00 ➝ $36.00	Low
1/3/2023	JPMorgan Chase & Co.	Boost Target	Overweight ➝ Overweight	3,450.00 ➝ 3,600.00	Low
12/20/2022	Citigroup	Downgrade	Buy ➝ Neutral		Low
11/17/2022	AlphaValue	Upgrade	Reduce		Low
11/15/2022	Cowen	Boost Target		$43.00	Low
11/14/2022	JPMorgan Chase & Co.	Boost Target	Overweight ➝ Overweight	2,900.00 ➝ 3,450.00	Low
11/14/2022	William Blair	Initiated Coverage	Market Perform		Low
11/11/2022	Deutsche Bank Aktiengesellschaft	Downgrade	Buy ➝ Hold		Low
11/10/2022	SVB Leerink	Boost Target	Market Perform	$33.00	Low
10/17/2022	DNB Markets	Downgrade	Buy ➝ Hold		Low
8/22/2022	HC Wainwright	Boost Target	Buy	$49.00 ➝ $51.00	Low
8/15/2022	Morgan Stanley	Boost Target	Underweight	$29.00 ➝ $31.00	Low
8/11/2022	SVB Leerink	Boost Target	Market Perform	$30.00 ➝ $31.00	Low
7/20/2022	HC Wainwright	Boost Target	Buy	$47.00 ➝ $49.00	Low
6/23/2022	BMO Capital Markets	Initiated Coverage	Market Perform	$34.73	Low
5/17/2022	Morgan Stanley	Lower Target	Underweight	$29.00	Medium
5/13/2022	Bryan, Garnier & Co	Upgrade	Sell ➝ Neutral		Medium
5/13/2022	Berenberg Bank	Upgrade	Sell ➝ Hold		Medium
5/2/2022	Cowen	Initiated Coverage	Market Perform	$38.00	Low
5/2/2022	Cowen	Initiated Coverage	Market Perform		Low
4/12/2022	Morgan Stanley	Lower Target	Underweight	$33.00 ➝ $30.00	Low
3/17/2022	HC Wainwright	Reiterated Rating	Buy	$47.00	Medium
3/16/2022	UBS Group	Upgrade	Neutral ➝ Buy		Medium
2/25/2022	JPMorgan Chase & Co.	Lower Target		3,200.00 ➝ 3,100.00	Low
2/17/2022	SVB Leerink	Lower Target	Market Perform	$42.00 ➝ $39.00	High
1/31/2022	HC Wainwright	Upgrade	Neutral ➝ Buy	$47.00	High
1/3/2022	Guggenheim	Downgrade	Buy ➝ Neutral		Low
12/1/2021	Berenberg Bank	Initiated Coverage	Sell		Low
9/20/2021	HC Wainwright	Reiterated Rating	Hold	$47.00	Low
9/16/2021	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$45.50 ➝ $48.00	Low
9/7/2021	Morgan Stanley	Downgrade	Equal Weight ➝ Underweight	$37.00	High
8/24/2021	HC Wainwright	Downgrade	Buy ➝ Neutral	$47.00	Low
8/20/2021	JPMorgan Chase & Co.	Reiterated Rating	Overweight		Medium
8/16/2021	Societe Generale	Reiterated Rating	Sell		Low
8/12/2021	Barclays	Reiterated Rating	Overweight		Low
8/12/2021	UBS Group	Reiterated Rating	Neutral		Low
8/12/2021	Royal Bank of Canada	Boost Target	Outperform	$46.00 ➝ $55.00	Medium
8/12/2021	SVB Leerink	Boost Target	Market Perform	$37.00 ➝ $42.00	Low
7/26/2021	HC Wainwright	Reiterated Rating	Buy	$47.00	Low
7/19/2021	Barclays	Reiterated Rating	Overweight		Medium
7/13/2021	HC Wainwright	Reiterated Rating	Buy	$47.00	Low
6/9/2021	JPMorgan Chase & Co.	Reiterated Rating	Overweight		Medium
6/7/2021	UBS Group	Reiterated Rating	Buy		Low
5/28/2021	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy		Low
5/17/2021	JPMorgan Chase & Co.	Reiterated Rating	Overweight		Low
4/20/2021	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy		Low
4/19/2021	Morgan Stanley	Lower Target	Equal Weight	$41.00 ➝ $37.00	Low
3/15/2021	DNB Markets	Upgrade	Sell ➝ Buy		Low
3/9/2021	JPMorgan Chase & Co.	Reiterated Rating	Overweight		Low
3/9/2021	UBS Group	Reiterated Rating	Buy		Low
2/25/2021	Truist Financial	Boost Target		$42.00 ➝ $47.00	Low
2/25/2021	SVB Leerink	Lower Target	Market Perform	$38.00 ➝ $36.00	High
2/24/2021	Barclays	Reiterated Rating	Overweight		High
2/24/2021	Danske	Upgrade	Hold ➝ Buy		Medium
2/11/2021	HC Wainwright	Reiterated Rating	Buy		Low
1/26/2021	SVB Leerink	Boost Target	Market Perform	$34.00 ➝ $38.00	Medium
1/25/2021	DNB Markets	Downgrade	Hold ➝ Sell		Medium
1/19/2021	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight		Low
1/15/2021	HC Wainwright	Boost Target	Buy	$44.00 ➝ $49.00	High
1/4/2021	Royal Bank of Canada	Boost Target	Positive ➝ Outperform	$40.00 ➝ $46.00	N/A
12/16/2020	Morgan Stanley	Boost Target	Overweight	$37.00 ➝ $41.00	Low
12/9/2020	SVB Leerink	Lower Target	Market Perform	$36.00 ➝ $34.00	Medium
11/25/2020	HC Wainwright	Lower Target	Buy	$45.00 ➝ $44.00	Low
11/16/2020	UBS Group	Reiterated Rating	Buy		Low
11/5/2020	Morgan Stanley	Boost Target	Overweight	$35.00 ➝ $37.00	Low
11/5/2020	HC Wainwright	Boost Target	Buy	$42.00 ➝ $45.00	Medium
10/27/2020	The Goldman Sachs Group	Boost Target	Neutral	$37.00	High
10/13/2020	Morgan Stanley	Boost Target	Overweight	$32.00 ➝ $35.00	Low
9/23/2020	HC Wainwright	Boost Target	Buy	$41.00 ➝ $42.00	High
9/23/2020	Bryan, Garnier & Co	Downgrade	Neutral ➝ Sell		High
9/8/2020	SVB Leerink	Initiated Coverage	Market Perform	$35.00	Low
8/24/2020	Truist Financial	Boost Target		$39.00 ➝ $41.00	Low
8/21/2020	HC Wainwright	Boost Target	Buy	$40.00 ➝ $41.00	Medium
8/13/2020	Royal Bank of Canada	Boost Target	Outperform	$35.00 ➝ $38.00	Low
8/13/2020	Morgan Stanley	Boost Target	Overweight	$30.00 ➝ $32.00	High
8/13/2020	HC Wainwright	Reiterated Rating	Buy		High
7/17/2020	HC Wainwright	Reiterated Rating	Buy	$40.00	Medium
7/2/2020	Societe Generale	Initiated Coverage	Sell		Low
6/30/2020	HC Wainwright	Reiterated Rating	Buy	$40.00	Medium
6/25/2020	Credit Suisse Group	Downgrade	Outperform ➝ Neutral		Low
6/19/2020	Royal Bank of Canada	Boost Target	Outperform	$27.00 ➝ $35.00	Low
6/12/2020	JPMorgan Chase & Co.	Reiterated Rating	Overweight		Low
6/11/2020	Barclays	Reiterated Rating	Overweight		Low
6/11/2020	SunTrust Banks	Boost Target	Buy	$36.00 ➝ $39.00	Medium
6/11/2020	HC Wainwright	Boost Target	Buy	$34.00 ➝ $40.00	Medium
6/3/2020	Barclays	Reiterated Rating	Overweight		Medium
6/3/2020	Bryan, Garnier & Co	Downgrade	Buy ➝ Neutral		Low
6/2/2020	SunTrust Banks	Boost Target	Buy	$30.00 ➝ $36.00	Low
6/2/2020	Danske	Downgrade	Buy ➝ Hold		Low
6/1/2020	HC Wainwright	Reiterated Rating	Positive ➝ Buy	$29.00 ➝ $34.00	Medium
5/26/2020	UBS Group	Upgrade	Neutral ➝ Buy		Low
5/7/2020	SunTrust Banks	Boost Target	Buy	$28.00 ➝ $30.00	Low
5/7/2020	HC Wainwright	Boost Target	Buy	$28.00 ➝ $29.00	Low
5/1/2020	HC Wainwright	Reiterated Rating	Buy	$28.00	High
4/23/2020	Credit Suisse Group	Initiated Coverage	Outperform		Low
4/15/2020	Morgan Stanley	Lower Target	Overweight	$31.00 ➝ $30.00	Low
4/15/2020	HC Wainwright	Lower Target	Buy	$29.00 ➝ $28.00	Low
4/6/2020	Royal Bank of Canada	Reiterated Rating	Buy	$27.00	Medium
3/4/2020	HC Wainwright	Reiterated Rating	Buy	$29.00	Low
2/24/2020	HC Wainwright	Reiterated Rating	Buy	$25.00 ➝ $29.00	Low
2/20/2020	Morgan Stanley	Boost Target	Overweight	$30.00 ➝ $31.00	Medium
2/11/2020	HC Wainwright	Reiterated Rating	Buy	$25.00	Medium
1/22/2020	HC Wainwright	Reiterated Rating	Buy	$25.00	Low
1/13/2020	SunTrust Banks	Initiated Coverage	Buy		Medium
12/12/2019	Deutsche Bank Aktiengesellschaft	Downgrade	Buy ➝ Hold		High
12/11/2019	HC Wainwright	Reiterated Rating	Buy	$25.00	High
12/4/2019	HC Wainwright	Reiterated Rating	Buy	$25.00	Low
11/20/2019	HC Wainwright	Reiterated Rating	Buy	$25.00	Low
10/16/2019	HC Wainwright	Boost Target	Buy	$24.00 ➝ $25.00	Low
9/27/2019	HC Wainwright	Set Target	Buy	$24.00	Low
9/16/2019	HC Wainwright	Reiterated Rating	Buy	$24.00	Low
9/13/2019	Bank of America	Upgrade	Neutral ➝ Buy		Medium
9/12/2019	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$23.00	Low
8/26/2019	HC Wainwright	Reiterated Rating	Buy		Low
8/12/2019	Guggenheim	Initiated Coverage	Buy ➝ Buy		Medium
8/12/2019	Royal Bank of Canada	Initiated Coverage	Outperform ➝ Outperform	$23.00	Low
8/12/2019	Morgan Stanley	Initiated Coverage	Overweight ➝ Overweight		Low

(Data available from 4/18/2019 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

7 very positive mentions
3 positive mentions
2 negative mentions
2 very negative mentions

Mentions as of

9/21/2023

3 very positive mentions
2 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

10/21/2023

0 very positive mentions
5 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

11/20/2023

4 very positive mentions
7 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

12/20/2023

7 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/19/2024

10 very positive mentions
18 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

2/18/2024

13 very positive mentions
30 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

3/19/2024

14 very positive mentions
18 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

4/18/2024

Current Sentiment

Recent Stories by Sentiment

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Today's Range

Now: $28.33

$28.29

$28.62

50 Day Range

MA: $29.36

$26.43

$31.68

52 Week Range

Now: $28.33

$26.32

$42.72

Volume

243,953 shs

Average Volume

594,322 shs

Market Capitalization

$18.73 billion

P/E Ratio

29.51

Dividend Yield

N/A

Beta

0.99

Frequently Asked Questions

What sell-side analysts currently cover shares of Genmab A/S?: The following Wall Street sell-side analysts have issued reports on Genmab A/S in the last year: BMO Capital Markets, BNP Paribas, BTIG Research, Citigroup Inc., Deutsche Bank Aktiengesellschaft, DNB Markets, HC Wainwright, HSBC Holdings plc, Morgan Stanley, Nordea Equity Research, Royal Bank of Canada, TheStreet, Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for GMAB.
What is the current price target for Genmab A/S?: 4 Wall Street analysts have set twelve-month price targets for Genmab A/S in the last year. Their average twelve-month price target is $48.50, suggesting a possible upside of 71.2%. Truist Financial Co. has the highest price target set, predicting GMAB will reach $50.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $46.00 for Genmab A/S in the next year.
View the latest price targets for GMAB.
What is the current consensus analyst rating for Genmab A/S?: Genmab A/S currently has 3 sell ratings, 2 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GMAB, but not buy more shares or sell existing shares.
View the latest ratings for GMAB.
What other companies compete with Genmab A/S?: Other companies that are similar to Genmab A/S include Alnylam Pharmaceuticals, BioMarin Pharmaceutical, Teva Pharmaceutical Industries, Viatris and BeiGene. Learn More about companies similar to Genmab A/S.
How do I contact Genmab A/S's investor relations team?: Genmab A/S's physical mailing address is Kalvebod Brygge 43, Copenhagen G7, 1560. The company's listed phone number is (457) 020-2728 and its investor relations email address is [email protected]. The official website for Genmab A/S is www.genmab.com. Learn More about contacing Genmab A/S investor relations.

Genmab A/S - GMAB Stock Price Target and Predictions

Analyst Price Target for GMAB

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.52 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Genmab A/S?

What is the current price target for Genmab A/S?

What is the current consensus analyst rating for Genmab A/S?

What other companies compete with Genmab A/S?

How do I contact Genmab A/S's investor relations team?